Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Coya Therapeutics, Inc. ( (COYA) ).
On January 8, 2026, Coya Therapeutics, Inc. reported positive results from an investigator-initiated, open-label proof-of-concept study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with frontotemporal dementia over six months at the Houston Methodist Neurological Institute. The regimen, consisting of subcutaneous CTLA4-Ig and a five-day course of low-dose IL-2 every four weeks for 22 weeks, showed a favorable safety profile with only mild injection-site erythema and no serious adverse events, while demonstrating significantly increased Treg suppressive function, Treg percentages, and associated biomarkers (CD25 and FOXP3) from two weeks through 22 weeks. Cognitive assessments using the Montreal Cognitive Assessment and CDR-FTLD scales showed no significant decline from baseline to week 22, suggesting potential disease stabilization in this small cohort and supporting further exploration of Coya’s Treg-targeted approach in FTD.
The most recent analyst rating on (COYA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.
Spark’s Take on COYA Stock
According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and materially negative cash flow, including a sharply worse TTM burn) and bearish technicals (below key moving averages with negative MACD). Offsetting factors include a clean debt profile/positive equity and constructive corporate progress (milestone payment, IND acceptance and trial launch, and financing that extends runway), while valuation provides limited support due to negative earnings and no dividend.
To see Spark’s full report on COYA stock, click here.
More about Coya Therapeutics, Inc.
Coya Therapeutics, Inc. is a biotechnology company focused on developing immunomodulatory therapies, including treatments targeting regulatory T cells (Tregs), for neurodegenerative diseases such as frontotemporal dementia (FTD). The company’s programs leverage combinations of biologic agents like low-dose interleukin-2 (IL-2) and CTLA4-Ig to enhance Treg function with the aim of modifying disease progression in difficult-to-treat neurological conditions.
Average Trading Volume: 239,026
Technical Sentiment Signal: Sell
Current Market Cap: $109.9M
Find detailed analytics on COYA stock on TipRanks’ Stock Analysis page.